Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 2/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27041207 | 0.88 | MEN1 (0.47) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL29486901 | 0.83 | SMN1; SMN2 (0.49) | BRD4MEN1KMT2APOLBTSHR | |
| SCHEMBL27057151 | 0.80 | TRPV1 (0.52) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL27057129 | 0.77 | MEN1 (0.49) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL29486866 | 0.74 | MEN1 (0.47) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL27041289 | 0.74 | MEN1 (0.47) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL29486836 | 0.74 | MEN1 (0.47) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL27041273 | 0.74 | MEN1 (0.47) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL6128121 | 0.73 | KDM4E (0.62) | MEN1KMT2APOLBTSHRSMN1; SMN2 | |
| SCHEMBL16295911 | 0.72 | ATM (0.47) | ATMBRD4BCHECNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. | 2024-06-20 | — | — | US | disclosed |
| WO-2022197862-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | BIOTHERYX, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240197888-A1 | SOS1 PROTEIN DEGRADERS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND THEIR THERAPEUTIC APPLICATIONS | SOS1, SOS2, SOST | ATM 2919/4885BRD4 4441/4885MEN1 439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.